

# **HIV-associated Lipodystrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Drug Treatment, Cosmetic Corrective Treatment), By Route of Administration (Oral, Injectables, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F**

<https://marketpublishers.com/r/H84935DF7059EN.html>

Date: January 2026

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: H84935DF7059EN

## **Abstracts**

The Global HIV-associated Lipodystrophy Market is projected to expand from USD 185.82 Million in 2025 to USD 228.62 Million by 2031, registering a CAGR of 3.52%. Defined as a metabolic syndrome involving abnormal fat redistribution such as lipoatrophy and lipohypertrophy, this condition frequently arises as an adverse reaction to antiretroviral regimens. Growth is primarily driven by the sustained rise in the global HIV-positive population and the extensive scale-up of antiretroviral therapy (ART) programs, which have extended patient life expectancy and increased exposure to long-term side effects. Furthermore, the clinical necessity to address cardiovascular risks linked to metabolic irregularities reinforces the demand for effective management strategies beyond mere aesthetic concerns.

However, market expansion is significantly impeded by the high cost of approved therapeutics and insufficient reimbursement frameworks, which restrict access for patients in low-to-middle-income regions. This economic obstacle remains a critical challenge despite the growing demographic requiring continuous care. According to UNAIDS, approximately 31.6 million individuals globally were accessing antiretroviral therapy by the end of 2024, highlighting a substantial increase in the population

potentially at risk of developing treatment-associated lipodystrophy.

## **Market Driver**

The rising global prevalence of HIV infection acts as the fundamental catalyst for market demand, as an increasing number of long-term survivors correlates directly with a higher incidence of metabolic complications. With antiretroviral therapies extending lifespans, patients remain on life-saving regimens for longer periods, thereby accumulating the risk of developing adverse fat redistribution syndromes like lipoatrophy and lipohypertrophy. This expanding patient base generates a continuous medical need for interventions to manage these chronic side effects. As per the UNAIDS 'Fact Sheet 2024' released in July 2024, roughly 39.9 million people globally were living with HIV in 2023, representing a massive patient pool potentially requiring care. Additionally, the Centers for Disease Control and Prevention reported in 2024 that an estimated 1.2 million people in the United States were living with HIV at the end of 2022, highlighting significant demand in high-value regional markets.

Concurrently, advancements in novel therapeutic agents and dermal fillers are accelerating revenue growth by evolving treatment options from basic management to effective aesthetic and metabolic restoration. The commercial availability of targeted growth hormone-releasing factors and specialized volumizing fillers has encouraged adoption among patients aiming to mitigate the stigmatizing physical changes associated with the condition. This sector is demonstrating strong financial results, indicating a willingness among healthcare systems and patients to invest in these solutions. For instance, Theratechnologies Inc. reported in their 'Q3 2024 Earnings Call Transcript' from October 2024 that net sales of EGRIFTA SV, an injectable for reducing excess abdominal fat in HIV-infected patients, reached USD 16.7 million in that quarter alone, proving that efficacious, approved products drive industry expansion despite economic hurdles.

## **Market Challenge**

The exorbitant costs of approved therapeutics combined with inadequate reimbursement policies serve as major restraints on the Global HIV-associated Lipodystrophy Market. These economic barriers create a substantial gap between the clinical necessity for treatment and the actual purchasing power of the affected population. Because lipodystrophy management is frequently classified as a secondary intervention relative to life-saving antiretroviral therapy, insurance coverage is often restricted or unavailable in many jurisdictions. As a result, manufacturers struggle to

penetrate low-to-middle-income markets where healthcare funds are rigorously allocated toward essential viral suppression, hindering the widespread uptake of approved drugs despite their clinical effectiveness.

This financial constraint is particularly acute given the immense scale of the global patient population requiring long-term management. While the market opportunity is theoretically extensive, it is practically limited by affordability challenges in high-burden regions, effectively capping potential revenue generation. According to UNAIDS, there were approximately 40.8 million people living with HIV worldwide in 2024. This vast patient base represents a significant unmet need, yet the market is unable to fully capitalize on this demand as long as high out-of-pocket costs and reimbursement deficiencies make treatments inaccessible for the majority of individuals living with the condition.

## **Market Trends**

The market landscape is being reshaped by the commercialization of advanced growth hormone-releasing factor formulations that prioritize patient adherence through improved delivery systems. Although earlier therapies demonstrated clinical efficacy, the industry is now shifting toward next-generation, user-friendly options that significantly alleviate the logistical burden of daily administration for long-term survivors. This progression tackles the critical challenge of "treatment fatigue" in chronic HIV care, promoting sustained therapeutic outcomes by simplifying complex regimens. According to the 'First Quarter 2025 Financial Results' from Theratechnologies Inc. in March 2025, the U.S. FDA approved EGRIFTA WR, a new F8 formulation of tesamorelin designed to treat excess visceral abdominal fat, marking a significant step forward in optimizing long-term metabolic management for this patient group.

Simultaneously, the rising adoption of minimally invasive dermal fillers is being driven by a surge in regenerative biostimulators that provide durable structural restoration surpassing transient volume correction. Unlike traditional hyaluronic acid alternatives, agents such as poly-L-lactic acid are securing substantial market share by stimulating the host's own collagen production, offering a more permanent physiological solution for facial lipoatrophy. This sub-segment has become a crucial revenue driver for major aesthetic portfolios, confirming the commercial trend toward regenerative medicine. As noted in the 'Annual Report 2024' by Galderma Group AG in March 2025, the company achieved record net sales of USD 4.41 billion, with its flagship biostimulator brand Sculptra acting as a primary growth engine within the injectable aesthetics category.

## Key Market Players

Theratechnologies Inc

Amryt Pharmaceuticals, Inc.

Fawn Incorporation

Abbott Laboratories, Inc.

Lupin Pharmaceuticals, Inc.

Pfizer Inc.

Bayer AG

Novartis Pharmaceuticals Corporation

AstraZeneca Plc

GlaxoSmithKline Plc

## Report Scope

In this report, the Global HIV-associated Lipodystrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV-associated Lipodystrophy Market, By Type

Drug Treatment

Cosmetic Corrective Treatment

HIV-associated Lipodystrophy Market, By Route of Administration

Oral

Injectables

Others

### HIV-associated Lipodystrophy Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

### HIV-associated Lipodystrophy Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

## **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the Global HIV-associated Lipodystrophy Market.

## **Available Customizations:**

Global HIV-associated Lipodystrophy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## **Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Type (Drug Treatment, Cosmetic Corrective Treatment)
  - 5.2.2. By Route of Administration (Oral, Injectables, Others)
  - 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map

## **6. NORTH AMERICA HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Type
  - 6.2.2. By Route of Administration
  - 6.2.3. By Distribution Channel
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States HIV-associated Lipodystrophy Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Type
      - 6.3.1.2.2. By Route of Administration
      - 6.3.1.2.3. By Distribution Channel
  - 6.3.2. Canada HIV-associated Lipodystrophy Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Type
      - 6.3.2.2.2. By Route of Administration
      - 6.3.2.2.3. By Distribution Channel
  - 6.3.3. Mexico HIV-associated Lipodystrophy Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Type
      - 6.3.3.2.2. By Route of Administration
      - 6.3.3.2.3. By Distribution Channel

## **7. EUROPE HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK**

- 7.1. Market Size & Forecast

- 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Type
  - 7.2.2. By Route of Administration
  - 7.2.3. By Distribution Channel
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany HIV-associated Lipodystrophy Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Type
      - 7.3.1.2.2. By Route of Administration
      - 7.3.1.2.3. By Distribution Channel
  - 7.3.2. France HIV-associated Lipodystrophy Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Type
      - 7.3.2.2.2. By Route of Administration
      - 7.3.2.2.3. By Distribution Channel
  - 7.3.3. United Kingdom HIV-associated Lipodystrophy Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Type
      - 7.3.3.2.2. By Route of Administration
      - 7.3.3.2.3. By Distribution Channel
  - 7.3.4. Italy HIV-associated Lipodystrophy Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Type
      - 7.3.4.2.2. By Route of Administration
      - 7.3.4.2.3. By Distribution Channel
  - 7.3.5. Spain HIV-associated Lipodystrophy Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value
    - 7.3.5.2. Market Share & Forecast

- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel

## **8. ASIA PACIFIC HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Type
  - 8.2.2. By Route of Administration
  - 8.2.3. By Distribution Channel
  - 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
  - 8.3.1. China HIV-associated Lipodystrophy Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Type
      - 8.3.1.2.2. By Route of Administration
      - 8.3.1.2.3. By Distribution Channel
  - 8.3.2. India HIV-associated Lipodystrophy Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Type
      - 8.3.2.2.2. By Route of Administration
      - 8.3.2.2.3. By Distribution Channel
  - 8.3.3. Japan HIV-associated Lipodystrophy Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Type
      - 8.3.3.2.2. By Route of Administration
      - 8.3.3.2.3. By Distribution Channel
  - 8.3.4. South Korea HIV-associated Lipodystrophy Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value
    - 8.3.4.2. Market Share & Forecast

- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia HIV-associated Lipodystrophy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

## **9. MIDDLE EAST & AFRICA HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Type
  - 9.2.2. By Route of Administration
  - 9.2.3. By Distribution Channel
  - 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
  - 9.3.1. Saudi Arabia HIV-associated Lipodystrophy Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Type
      - 9.3.1.2.2. By Route of Administration
      - 9.3.1.2.3. By Distribution Channel
  - 9.3.2. UAE HIV-associated Lipodystrophy Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Type
      - 9.3.2.2.2. By Route of Administration
      - 9.3.2.2.3. By Distribution Channel
  - 9.3.3. South Africa HIV-associated Lipodystrophy Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value

- 9.3.3.2. Market Share & Forecast
  - 9.3.3.2.1. By Type
  - 9.3.3.2.2. By Route of Administration
  - 9.3.3.2.3. By Distribution Channel

## **10. SOUTH AMERICA HIV-ASSOCIATED LIPODYSTROPHY MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Type
  - 10.2.2. By Route of Administration
  - 10.2.3. By Distribution Channel
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil HIV-associated Lipodystrophy Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Type
      - 10.3.1.2.2. By Route of Administration
      - 10.3.1.2.3. By Distribution Channel
  - 10.3.2. Colombia HIV-associated Lipodystrophy Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Type
      - 10.3.2.2.2. By Route of Administration
      - 10.3.2.2.3. By Distribution Channel
  - 10.3.3. Argentina HIV-associated Lipodystrophy Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Type
      - 10.3.3.2.2. By Route of Administration
      - 10.3.3.2.3. By Distribution Channel

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

## **13. GLOBAL HIV-ASSOCIATED LIPODYSTROPHY MARKET: SWOT ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

- 15.1. Theratechnologies Inc
  - 15.1.1. Business Overview
  - 15.1.2. Products & Services
  - 15.1.3. Recent Developments
  - 15.1.4. Key Personnel
  - 15.1.5. SWOT Analysis
- 15.2. Amryt Pharmaceuticals, Inc.
- 15.3. Fawn Incorporation
- 15.4. Abbott Laboratories, Inc.
- 15.5. Lupin Pharmaceuticals, Inc.
- 15.6. Pfizer Inc.
- 15.7. Bayer AG
- 15.8. Novartis Pharmaceuticals Corporation
- 15.9. AstraZeneca Plc
- 15.10. GlaxoSmithKline Plc

## **16. STRATEGIC RECOMMENDATIONS**

## 17. ABOUT US & DISCLAIMER

## I would like to order

Product name: HIV-associated Lipodystrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Drug Treatment, Cosmetic Corrective Treatment), By Route of Administration (Oral, Injectables, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/H84935DF7059EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H84935DF7059EN.html>